HALO Share Price

Open 13.32 Change Price %
High 13.62 1 Day 0.20 1.50
Low 13.10 1 Week -1.19 -8.11
Close 13.49 1 Month 1.45 12.04
Volume 1047367 1 Year 4.56 51.06
52 Week High 15.20
52 Week Low 7.70
HALO Important Levels
Resistance 2 13.97
Resistance 1 13.77
Pivot 13.40
Support 1 13.21
Support 2 13.01
NASDAQ USA Most Active Stocks
FTR 2.11 -10.59%
FTR 2.11 -10.59%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
BGMD 0.06 20.00%
HAUP 0.06 20.00%
IDRA 2.49 19.14%
CLNT 3.08 16.23%
CGEI 0.36 16.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
VALV 0.02 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Halozyme Therapeutics, Inc. (NASDAQ: HALO)

HALO Technical Analysis 4
As on 22nd Mar 2017 HALO Share Price closed @ 13.49 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 10.82 & Buy for SHORT-TERM with Stoploss of 12.51 we also expect STOCK to react on Following IMPORTANT LEVELS.
HALO Target for March
1st Target up-side 14.02
2nd Target up-side 14.87
3rd Target up-side 15.71
1st Target down-side 11.62
2nd Target down-side 10.77
3rd Target down-side 9.93
HALO Other Details
Segment EQ
Market Capital 613046848.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.halozyme.com
HALO Address
HALO
11388 Sorrento Valley Road
San Diego, CA 92121
United States
Phone: 858-794-8889
Fax: 858-704-8311
HALO Latest News
Interactive Technical Analysis Chart Halozyme Therapeutics, Inc. ( HALO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Halozyme Therapeutics, Inc.
HALO Business Profile
Halozyme Therapeutics, Inc. is a biopharmaceutical company. The Company�s research focuses primarily on human enzymes that alter the extracellular matrix. The Company�s pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology. The product candidates in its pipeline are based on rHuPH20, a patented human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA), a naturally occurring substance that is a component of the extracellular matrix in tissues throughout the body, such as skin and cartilage. The Company has collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Pfizer Inc. (Pfizer), Baxter Healthcare Corporation (Baxter), ViroPharma Incorporated (ViroPharma) and Intrexon Corporation (Intrexon), with three product candidates.